DEF 14C: Sunshine Biopharma Announces Reverse Stock Split to Regain Nasdaq Compliance

Sunshine Biopharma intends to effectuate a reverse stock split of up to 1-for-200 to regain compliance with Nasdaq listing requirements.

Summary

• Sunshine Biopharma is implementing a reverse stock split to address non-compliance with Nasdaq's minimum bid price and low-priced stock rules.
• The company received notification from Nasdaq regarding its failure to meet the minimum bid requirement of $1.00 per share and the low-priced stock rule.
• To regain compliance, Sunshine Biopharma's board has approved a reverse stock split with a ratio of up to 1-for-200, with the exact ratio to be determined by the board.
• The reverse stock split was approved by written consent from Dr. Steve Slilaty, the CEO, who holds approximately 57.4% of the company's voting securities.
• The company currently has 99,452,865 shares of common stock issued and outstanding.
• If the maximum reverse stock split ratio is applied, the number of outstanding shares will be reduced to approximately 497,265.
• The effective date of the reverse stock split is anticipated to occur in April 2024.
• The company has appealed Nasdaq's delisting determination, and a hearing is scheduled for April 25, 2024.
• The reverse stock split will increase the per-share loss and net book value of the common stock.
• The company will continue to have 3,000,000,000 authorized shares of common stock after the reverse stock split.

Sentiment

Score: 4

Explanation: The announcement is a necessary step to maintain Nasdaq listing, but it reflects underlying issues with the company's stock price and market valuation. The high reverse split ratio suggests significant challenges.

Positives

• The reverse stock split aims to increase the per-share trading price of the common stock, potentially improving marketability and liquidity.
• The company has appealed Nasdaq's delisting determination, which has stayed the delisting action pending a final decision.
• The company believes that regaining compliance with Nasdaq standards will encourage interest and trading in the common stock.

Negatives

• The company is currently not in compliance with Nasdaq's minimum bid price and low-priced stock rules.
• The reverse stock split will reduce the number of outstanding shares, which could adversely affect the liquidity of the common stock.
• There is no guarantee that the market price per share will rise in proportion to the reduction in the number of shares outstanding.
• The reverse stock split could potentially have anti-takeover effects by increasing the number of authorized but unissued shares.

Risks

• The market price of the company's common stock may decline after the reverse stock split.
• The company's appeal to Nasdaq may not be successful, potentially leading to delisting.
• The increased number of authorized but unissued shares could be used to resist or frustrate a third-party transaction.

Future Outlook

The company intends to effectuate the reverse stock split in April 2024 to regain compliance with Nasdaq listing requirements and improve the marketability and liquidity of its common stock.

Management Comments

• The Board believes that the increased market price of the Common Stock expected as a result of implementing the Reverse Stock Split will improve the marketability and liquidity of the Common Stock for our stockholders and will encourage interest and trading in the Common Stock.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low share prices. Other companies in the biotech or pharmaceutical industries that have faced similar situations include [Comparable Company 1] and [Comparable Company 2].

Comparison to Industry Standards

• Many companies facing Nasdaq delisting due to low share prices implement reverse stock splits to regain compliance.
• The success of a reverse stock split in increasing share price and maintaining listing status varies widely and depends on company-specific factors and market conditions.
• Compared to other companies that have implemented reverse stock splits, Sunshine Biopharma's 1-for-200 ratio is relatively high, suggesting a significant need to increase the share price.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the company hopes the value of each share will increase.
• Employees may be affected by the company's ability to remain listed on Nasdaq, which could impact morale and job security.
• The company's suppliers and creditors may be impacted by the company's financial stability and ability to meet its obligations.

Next Steps

• The company will determine the exact ratio of the reverse stock split.
• The company will file the Articles of Amendment to the Company's Articles of Incorporation with the Secretary of State of the State of Colorado.
• The company will await the final written decision by the Nasdaq Hearings Panel regarding its appeal of the delisting determination.
• The company will notify Nasdaq and its stockholders of the effective date of the reverse stock split.

Key Dates

Keywords

reverse stock split, Nasdaq, compliance, minimum bid price, delisting, common stock, Sunshine Biopharma